Kraan Heleen, van der Stel Wanda, Kersten Gideon, Amorij Jean-Pierre
a Department of Research, Intravacc (Institute for Translational Vaccinology) , Bilthoven , The Netherlands.
b Division of Drug Delivery Technology , Leiden Academic Center for Drug Research, Leiden University , Leiden , The Netherlands.
Expert Rev Vaccines. 2016 Aug;15(8):1029-40. doi: 10.1586/14760584.2016.1158650. Epub 2016 Mar 16.
Global polio eradication is closer than ever. Replacement of the live attenuated oral poliovirus vaccine (OPV) by inactivated poliovirus vaccine (IPV) is recommended to achieve complete eradication. Limited global production capacity and relatively high IPV costs compared to OPV spur the need for improved polio vaccines. The target product profile of these vaccines includes not only dose sparing but also high stability, which is important for stockpiling, and easy application important for (emergency) vaccination campaigns. In this review, the current status of alternative polio vaccine delivery strategies is given. Furthermore, we discuss the feasibility of these strategies by highlighting challenges, hurdles to overcome, and formulation issues relevant for optimal vaccine delivery.
全球消灭脊髓灰质炎比以往任何时候都更接近目标。建议用灭活脊髓灰质炎病毒疫苗（IPV）替代减毒活口服脊髓灰质炎病毒疫苗（OPV），以实现彻底消灭。与OPV相比，全球生产能力有限以及IPV成本相对较高，促使人们需要改进脊髓灰质炎疫苗。这些疫苗的目标产品特性不仅包括减少剂量，还包括高稳定性（这对储存很重要）以及易于应用（这对（紧急）疫苗接种运动很重要）。在本综述中，介绍了替代脊髓灰质炎疫苗递送策略的现状。此外，我们通过强调挑战、需要克服的障碍以及与最佳疫苗递送相关的制剂问题，来讨论这些策略的可行性。
